Literature DB >> 1959474

Benefits and limitations of very-low-calorie diet therapy in obese NIDDM.

R R Henry1, B Gumbiner.   

Abstract

Weight reduction is one of the most effective therapies for obese non-insulin-dependent diabetes mellitus (NIDDM), but the success rate with conventional diets has been disappointing. The development of very-low-calorie diets (VLCDs) over the last two decades has provided an alternative approach to the treatment of uncomplicated obesity and is increasingly being used to treat obese NIDDM. This review focuses on the role of VLCDs in the treatment of obese NIDDM, the mechanisms underlying their efficacy, and the controversies surrounding their use. VLCDs provide 400-800 cal/day of high-quality protein and carbohydrate fortified with vitamins, minerals, and trace elements. Weight loss is initially very rapid, followed by steady reduction at a rate of 1-3 kg/wk. Metabolic benefits occur quickly with only modest weight reduction, suggesting that caloric restriction plays a more critical role. Multiple mechanisms account for improved glycemic control, including reduced hepatic glucose output, increased insulin action in the liver and peripheral tissues, and enhanced insulin secretion. VLCDs have the added benefit of rapid improvement in concomitant medical problems, particularly hypertension and hyperlipidemia, that could otherwise accelerate the development of some diabetic complications. Numerous controversies surround VLCD therapy, the most critical of which is its safety. However, recent studies indicate that VLCDs are safe for use by obese NIDDM patients in a medical setting closely supervised by an experienced physician. Contraindications to the diet, side effects, and recommended management are reviewed, as well as the role of adjunctive treatments, including behavioral modification and exercise. We present the perspective that, in most cases, the numerous metabolic benefits derived from VLCD therapy by the obese NIDDM patient outweigh its risks. Furthermore, recent data suggest that VLCD therapy may provide long-term benefits to the obese diabetic patient, despite weight regain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959474     DOI: 10.2337/diacare.14.9.802

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  25 in total

1.  Studies in insulin resistance following very low calorie diet and/or gastric bypass surgery.

Authors:  Jonathan Foo; Jeremy Krebs; Mark Thomas Hayes; Damon Bell; Donia Macartney-Coxson; Tony Croft; Richard Strawson Stubbs
Journal:  Obes Surg       Date:  2011-12       Impact factor: 4.129

2.  Impairment of body mass reduction-associated activation of brown/beige adipose tissue in patients with type 2 diabetes mellitus.

Authors:  S Rodovalho; B Rachid; J C De-Lima-Junior; S van de Sande-Lee; J Morari; H M Carvalho; B J Amorim; A J Tincani; E Chaim; J C Pareja; M J Saad; F Folli; C D Ramos; B Geloneze; L A Velloso
Journal:  Int J Obes (Lond)       Date:  2017-07-03       Impact factor: 5.095

Review 3.  Caloric restriction and chronic inflammatory diseases.

Authors:  O A González; C Tobia; J L Ebersole; M J Novak
Journal:  Oral Dis       Date:  2011-07-13       Impact factor: 3.511

4.  Weight Loss as a Cure for Type 2 Diabetes? Fact or Fantasy.

Authors:  Sangeeta R Kashyap; Emily S Louis; John P Kirwan
Journal:  Expert Rev Endocrinol Metab       Date:  2011-07-01

5.  Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients.

Authors:  V Ricca; E Mannucci; M Di Bernardo; S M Rizzello; P L Cabras; C M Rotella
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

6.  Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk.

Authors:  Harold Bays; Helena W Rodbard; Alan Bruce Schorr; J Michael González-Campoy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 7.  Management of the metabolic syndrome and type 2 diabetes through lifestyle modification.

Authors:  Faidon Magkos; Mary Yannakoulia; Jean L Chan; Christos S Mantzoros
Journal:  Annu Rev Nutr       Date:  2009       Impact factor: 11.848

8.  Short cycles of very low calorie diet in the therapy of obese type II diabetes mellitus.

Authors:  C M Rotella; B Cresci; E Mannucci; S M Rizzello; G Colzi; G Galli; S Giannini; G Messeri; F Piani; R Vannini
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

9.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.

Authors:  Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2009-01-25       Impact factor: 22.682

10.  Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study.

Authors:  Zhaoping Li; Kurt Hong; Ian Yip; Sergio Huerta; Susan Bowerman; Joseph Walker; Hejing Wang; Robert Elashoff; Vay Liang W Go; David Heber
Journal:  Curr Ther Res Clin Exp       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.